153 related articles for article (PubMed ID: 17045168)
1. Evaluation of 177Lu-DOTA-labeled aglycosylated monoclonal anti-L1-CAM antibody chCE7: influence of the number of chelators on the in vitro and in vivo properties.
Knogler K; Grünberg J; Novak-Hofer I; Zimmermann K; Schubiger PA
Nucl Med Biol; 2006 Oct; 33(7):883-9. PubMed ID: 17045168
[TBL] [Abstract][Full Text] [Related]
2. L1-CAM-targeted antibody therapy and (177)Lu-radioimmunotherapy of disseminated ovarian cancer.
Fischer E; Grünberg J; Cohrs S; Hohn A; Waldner-Knogler K; Jeger S; Zimmermann K; Novak-Hofer I; Schibli R
Int J Cancer; 2012 Jun; 130(11):2715-21. PubMed ID: 21796623
[TBL] [Abstract][Full Text] [Related]
3. DOTA-functionalized polylysine: a high number of DOTA chelates positively influences the biodistribution of enzymatic conjugated anti-tumor antibody chCE7agl.
Grünberg J; Jeger S; Sarko D; Dennler P; Zimmermann K; Mier W; Schibli R
PLoS One; 2013; 8(4):e60350. PubMed ID: 23565233
[TBL] [Abstract][Full Text] [Related]
4. In vivo evaluation of 177Lu- and 67/64Cu-labeled recombinant fragments of antibody chCE7 for radioimmunotherapy and PET imaging of L1-CAM-positive tumors.
Grünberg J; Novak-Hofer I; Honer M; Zimmermann K; Knogler K; Bläuenstein P; Ametamey S; Maecke HR; Schubiger PA
Clin Cancer Res; 2005 Jul; 11(14):5112-20. PubMed ID: 16033825
[TBL] [Abstract][Full Text] [Related]
5. Anti-L1CAM radioimmunotherapy is more effective with the radiolanthanide terbium-161 compared to lutetium-177 in an ovarian cancer model.
Grünberg J; Lindenblatt D; Dorrer H; Cohrs S; Zhernosekov K; Köster U; Türler A; Fischer E; Schibli R
Eur J Nucl Med Mol Imaging; 2014 Oct; 41(10):1907-15. PubMed ID: 24859811
[TBL] [Abstract][Full Text] [Related]
6. Copper-67 radioimmunotherapy and growth inhibition by anti-L1-cell adhesion molecule monoclonal antibodies in a therapy model of ovarian cancer metastasis.
Knogler K; Grünberg J; Zimmermann K; Cohrs S; Honer M; Ametamey S; Altevogt P; Fogel M; Schubiger PA; Novak-Hofer I
Clin Cancer Res; 2007 Jan; 13(2 Pt 1):603-11. PubMed ID: 17255283
[TBL] [Abstract][Full Text] [Related]
7. Antitenascin antibody 81C6 armed with 177Lu: in vivo comparison of macrocyclic and acyclic ligands.
Yordanov AT; Hens M; Pegram C; Bigner DD; Zalutsky MR
Nucl Med Biol; 2007 Feb; 34(2):173-83. PubMed ID: 17307125
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and evaluation of novel bifunctional chelating agents based on 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid for radiolabeling proteins.
Chappell LL; Ma D; Milenic DE; Garmestani K; Venditto V; Beitzel MP; Brechbiel MW
Nucl Med Biol; 2003 Aug; 30(6):581-95. PubMed ID: 12900284
[TBL] [Abstract][Full Text] [Related]
9. Comparison of DOTA and NODAGA as chelators for (64)Cu-labeled immunoconjugates.
Ghosh SC; Pinkston KL; Robinson H; Harvey BR; Wilganowski N; Gore K; Sevick-Muraca EM; Azhdarinia A
Nucl Med Biol; 2015 Feb; 42(2):177-83. PubMed ID: 25457653
[TBL] [Abstract][Full Text] [Related]
10. Preparation and biological evaluation of 111In-, 177Lu- and 90Y-labeled DOTA analogues conjugated to B72.3.
Mohsin H; Fitzsimmons J; Shelton T; Hoffman TJ; Cutler CS; Lewis MR; Athey PS; Gulyas G; Kiefer GE; Frank RK; Simon J; Lever SZ; Jurisson SS
Nucl Med Biol; 2007 Jul; 34(5):493-502. PubMed ID: 17591549
[TBL] [Abstract][Full Text] [Related]
11. Effect of Number of Bifunctional Chelating Agents on the Pharmacokinetics and Immunoreactivity of 177Lu-labeled Rituximab: A Systemic Study.
Guleria M; Das T; Kumar C; Sharma R; Amirdhanayagam J; Sarma HD; Dash A
Anticancer Agents Med Chem; 2018; 18(1):146-153. PubMed ID: 28745238
[TBL] [Abstract][Full Text] [Related]
12. In vivo comparison of macrocyclic and acyclic ligands for radiolabeling of monoclonal antibodies with 177Lu for radioimmunotherapeutic applications.
Milenic DE; Garmestani K; Chappell LL; Dadachova E; Yordanov A; Ma D; Schlom J; Brechbiel MW
Nucl Med Biol; 2002 May; 29(4):431-42. PubMed ID: 12031878
[TBL] [Abstract][Full Text] [Related]
13. Radiolanthanide-labeled monoclonal antibody CC49 for radioimmunotherapy of cancer: biological comparison of DOTA conjugates and 149Pm, 166Ho, and 177Lu.
Mohsin H; Jia F; Sivaguru G; Hudson MJ; Shelton TD; Hoffman TJ; Cutler CS; Ketring AR; Athey PS; Simón J; Frank RK; Jurisson SS; Lewis MR
Bioconjug Chem; 2006; 17(2):485-92. PubMed ID: 16536481
[TBL] [Abstract][Full Text] [Related]
14. Panitumumab Modified with Metal-Chelating Polymers (MCP) Complexed to
Aghevlian S; Lu Y; Winnik MA; Hedley DW; Reilly RM
Mol Pharm; 2018 Mar; 15(3):1150-1159. PubMed ID: 29314858
[TBL] [Abstract][Full Text] [Related]
15. 90Y-DOTA-hLL2: an agent for radioimmunotherapy of non-Hodgkin's lymphoma.
Griffiths GL; Govindan SV; Sharkey RM; Fisher DR; Goldenberg DM
J Nucl Med; 2003 Jan; 44(1):77-84. PubMed ID: 12515879
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and biodistribution of 177Lu-labeled multivalent single-chain Fv construct of the pancarcinoma monoclonal antibody CC49.
Chauhan SC; Jain M; Moore ED; Wittel UA; Li J; Gwilt PR; Colcher D; Batra SK
Eur J Nucl Med Mol Imaging; 2005 Mar; 32(3):264-73. PubMed ID: 15791435
[TBL] [Abstract][Full Text] [Related]
17. Mono(pyridine-N-oxide) DOTA analog and its G1/G4-PAMAM dendrimer conjugates labeled with 177Lu: radiolabeling and biodistribution studies.
Laznickova A; Biricova V; Laznicek M; Hermann P
Appl Radiat Isot; 2014 Feb; 84():70-7. PubMed ID: 24333746
[TBL] [Abstract][Full Text] [Related]
18. Combination of lutetium-177 labelled anti-L1CAM antibody chCE7 with the clinically relevant protein kinase inhibitor MK1775: a novel combination against human ovarian carcinoma.
Lindenblatt D; Terraneo N; Pellegrini G; Cohrs S; Spycher PR; Vukovic D; Béhé M; Schibli R; Grünberg J
BMC Cancer; 2018 Sep; 18(1):922. PubMed ID: 30253737
[TBL] [Abstract][Full Text] [Related]
19. Radioimmunotherapy of a human lung cancer xenograft with monoclonal antibody RS7: evaluation of (177)Lu and comparison of its efficacy with that of (90)Y and residualizing (131)I.
Stein R; Govindan SV; Chen S; Reed L; Richel H; Griffiths GL; Hansen HJ; Goldenberg DM
J Nucl Med; 2001 Jun; 42(6):967-74. PubMed ID: 11390564
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
